An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis

Trial Profile

An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Risperidone (Primary) ; Olanzapine; Quetiapine
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Janssen Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2009 Additional therapeutic area (PEC) identified as reported by ClinicalTrials.gov.
    • 12 May 2009 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top